Accelerate

Accelerate is a ground-breaking support programme aligned with the Wellbeing of Future Generations Act and A Healthier Wales.

Part funded by the European Regional Development Fund through the Welsh Government; it focuses on the delivery of innovative healthcare solutions pan Wales.

Accelerate was established to facilitate the translational pipeline from the identification of ‘real’ healthcare needs, through to the delivery of evidence-based innovation. This is being enabled by collaborations between clinicians, industry, academia and the third sector, and is led by the Life Sciences Hub Wales and three partner universities across Wales.

The Clinical Innovation Accelerator (CIA)

Here within Cardiff University, the School of Medicine plays host to one of the Accelerate partners; the Clinical Innovation Accelerator (CIA). The CIA sits within the Clinical Innovation Hub and is supported by the Clinical Innovation Partnership between Cardiff University and Cardiff and Vale Health Board.

CIA provides expertise in accelerating the delivery of clinically focused innovation through an experienced team of professionals with capabilities derived from academia, project management, research, health economics, engagement, industry, innovation and clinical practice.

Close working relationships with academic experts, NHS Health Boards, and industrial partners, enables new ideas to be focused into real world clinical/ healthcare practices and procedures, aided through a user-centric delivery model. Adopting a user-needs approach to building projects underpins the likelihood of future sustainability and enhances the pathways to impact.

Outputs of the CIA

Outputs generated from CIA led collaborations are being realised through a range of platform and pilot-based projects, ranging from changes in clinical and sustainable healthcare practices, to the development of artificial intelligence applications, evaluations, and new product development.

An array of data is being generated which may inform research-driven innovation beyond the initial projects. This includes an abundance of increasingly important real–world data, including patient-reported outcome and experience measures.

In the current COVID crisis, the CIA is demonstrating its situational relevance and responsiveness by contributing to the essential COVID work being delivered through Cardiff University’s category 3 laboratory. This is being actioned via the support for research associates to undertake this time sensitive work within Cardiff’s dedicated facilities.

CIA’s contribution to the Accelerate Programme is enabling distinct opportunities to realise and accelerate novel, innovative solutions, through effective research, development and innovation-focused collaborations.

This work is underpinning a legacy of evidence-based healthcare innovation, delivering on Welsh government priorities, and supporting lasting impact across life sciences and health and care services in Wales.

Through these effective collaborations, the sharing of expert knowledge, resources and processes is bolstering the translation of innovative ideas into sustainable solutions bringing value to Wales.

Find out more about the programme

To find out more, please download our brochure or feel free to contact us.

Funding provided by

Accelerate case studies

View all case studies.

Health economics reports

The Clinical Innovation Accelerator’s (CIA) series of health economic reports on clinical innovation topics are available to all our stakeholders.

Types of report

1. Health economic Insight Reports are high level economic reviews of a clinical innovation. They are intended as briefings for interested stakeholders.
2. Health economic Rationales address the specific question: 'What economic benefits could a clinical innovation realistically achieve?'. They are intended to help stakeholders decide whether to start a pilot or a clinical trial.
3. Health economic Assessment Reports address the specific question: 'To what degree does an innovation work, and at what cost?'. They are intended to help stakeholders decide whether to continue, pause or stop an existing pilot or trial.
4. Health economic Clinical Trial Reports include analyses of the cost-effectiveness or cost-utility of health outcomes reported by clinical trials. They are intended to be produced at the end of studies into clinical effectiveness.
5. CIA health economic Strategy Reports are reviews of the strategic behaviour and choices facing suppliers and consumers/adopters in a market for a clinical innovation. They are intended as briefings for interested stakeholders.
6. CIA business case Guides are 'How to guides' for making an economic case for a clinical innovation. They are intended as briefings for interested stakeholders.

Published reports